{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T07:34:07Z","timestamp":1768894447766,"version":"3.49.0"},"reference-count":46,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2011,12,1]],"date-time":"2011-12-01T00:00:00Z","timestamp":1322697600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2011,12,1]],"date-time":"2011-12-01T00:00:00Z","timestamp":1322697600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","internationaljournalofcardiology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Cardiology"],"published-print":{"date-parts":[[2011,12]]},"DOI":"10.1016\/j.ijcard.2010.08.043","type":"journal-article","created":{"date-parts":[[2010,9,17]],"date-time":"2010-09-17T06:15:05Z","timestamp":1284704105000},"page":"141-147","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"title":["Influence of age, gender, and race on the efficacy of adding ezetimibe to atorvastatin vs. atorvastatin up-titration in patients at moderately high or high risk for coronary heart disease"],"prefix":"10.1016","volume":"153","author":[{"given":"Harold E.","family":"Bays","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Scott E.","family":"Conard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lawrence A.","family":"Leiter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven R.","family":"Bird","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert S.","family":"Lowe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew M.","family":"Tershakovec","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijcard.2010.08.043_bb0005","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1161\/01.CIR.0000133317.49796.0E","article-title":"Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines","volume":"110","author":"Grundy","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2010.08.043_bb0010","first-page":"E46","article-title":"Heart disease and stroke statistics \u2014 2010 update. A report from the American Heart Association","volume":"121","author":"Lloyd-Jones","year":"2010","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2010.08.043_bb0015","doi-asserted-by":"crossref","first-page":"917","DOI":"10.2165\/11318270-000000000-00000","article-title":"Lipid-lowering therapy for the primary prevention of cardiovascular disease in the elderly opportunities and challenges","volume":"26","author":"Robinson","year":"2009","journal-title":"Drugs Aging"},{"key":"10.1016\/j.ijcard.2010.08.043_bb0020","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.maturitas.2008.12.013","article-title":"Assessing coronary heart disease in women","volume":"62","author":"Rollini","year":"2009","journal-title":"Maturitas"},{"key":"10.1016\/j.ijcard.2010.08.043_bb0025","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1016\/j.jacc.2009.04.098","article-title":"Women and ischemic heart disease: evolving knowledge","volume":"54","author":"Shaw","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ijcard.2010.08.043_bb0030","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1001\/archinte.161.4.514","article-title":"Cardiovascular disease and dyslipidemia in women","volume":"161","author":"Welty","year":"2001","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.ijcard.2010.08.043_bb0035","doi-asserted-by":"crossref","first-page":"12A","DOI":"10.1016\/j.amjcard.2005.11.011","article-title":"Coronary artery disease in minority racial and ethnic groups in the United States","volume":"97","author":"Ferdinand","year":"2006","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ijcard.2010.08.043_bb0040","doi-asserted-by":"crossref","first-page":"2565","DOI":"10.1001\/archinte.162.22.2565","article-title":"Risk factors for coronary heart disease in African Americans \u2014 the Atherosclerosis Risk in Communities Study, 1987\u20131997","volume":"162","author":"Jones","year":"2002","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.ijcard.2010.08.043_bb0045","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1016\/j.amjmed.2005.04.041","article-title":"Cardiovascular risk factors in minorities","volume":"118","author":"LaRosa","year":"2005","journal-title":"Am J Med"},{"key":"10.1016\/j.ijcard.2010.08.043_bb0050","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1111\/j.1368-5031.2004.00289.x","article-title":"Efficacy and safety of ezetimibe coadministered with statins: randomised, placebo-controlled, blinded experience in 2382 patients with primary hypercholesterolemia","volume":"58","author":"Davidson","year":"2004","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.ijcard.2010.08.043_bb0055","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/j.clinthera.2006.06.001","article-title":"Comparison of the lipid-modifying efficacy and safety profiles of ezetimibe coadministered with simvastatin in older versus younger patients with primary hypercholesterolemia: a post hoc analysis of subpopulations from three pooled clinical trials","volume":"28","author":"Feldman","year":"2006","journal-title":"Clin Ther"},{"key":"10.1016\/j.ijcard.2010.08.043_bb0060","doi-asserted-by":"crossref","first-page":"620","DOI":"10.4065\/79.5.620","article-title":"Efficacy and safety of ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia: a randomized, double-blind, placebo-controlled trial","volume":"79","author":"Goldberg","year":"2004","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.ijcard.2010.08.043_bb0065","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.2165\/00002512-200421150-00005","article-title":"Efficacy and safety of coadministration of ezetimibe and statins in elderly patients with primary hypercholesterolaemia","volume":"21","author":"Lipka","year":"2004","journal-title":"Drugs Aging"},{"key":"10.1016\/j.ijcard.2010.08.043_bb0070","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1089\/jwh.2004.13.1101","article-title":"Consistency in efficacy and safety of ezetimibe coadministered with statins for treatment of hypercholesterolemia in women and men","volume":"13","author":"Bennett","year":"2004","journal-title":"J Womens Health Larchmt"},{"key":"10.1016\/j.ijcard.2010.08.043_bb0075","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.4065\/81.9.1177","volume":"81","author":"Pearson","year":"2006","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.ijcard.2010.08.043_bb0080","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1185\/030079906X100131","article-title":"Consistency of lipid-altering effects of ezetimibe\/simvastatin across gender, race, age, baseline low density lipoprotein cholesterol levels, and coronary heart disease status: results of a pooled retrospective analysis","volume":"22","author":"Ose","year":"2006","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.ijcard.2010.08.043_bb0085","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1016\/j.amjcard.2008.09.075","article-title":"Efficacy and safety of ezetimibe added on to atorvastatin (20mg) versus uptitration of atorvastatin (to 40mg) in hypercholesterolemic patients at moderately high risk for coronary heart disease","volume":"102","author":"Conard","year":"2008","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ijcard.2010.08.043_bb0090","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1016\/j.amjcard.2008.09.076","article-title":"Efficacy and safety of ezetimibe added on to atorvastatin (40mg) compared with uptitration of atorvastatin (to 80mg) in hypercholesterolemic patients at high risk of coronary heart disease","volume":"102","author":"Leiter","year":"2008","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ijcard.2010.08.043_bb0095","doi-asserted-by":"crossref","first-page":"33","DOI":"10.2165\/00003088-200544010-00002","article-title":"The influence of age and sex on the clearance of cytochrome P450 3A substrates","volume":"44","author":"Cotreau","year":"2005","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.ijcard.2010.08.043_bb0100","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1517\/13543784.11.11.1587","article-title":"Ezetimibe","volume":"11","author":"Bays","year":"2002","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.ijcard.2010.08.043_bb0105","series-title":"Zetia (ezetimibe) tablets [package insert]","year":"2009"},{"key":"10.1016\/j.ijcard.2010.08.043_bb0110","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1002\/j.1552-4604.1996.tb04194.x","article-title":"Effect of age and gender on pharmacokinetics of atorvastatin in humans","volume":"36","author":"Gibson","year":"1996","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.ijcard.2010.08.043_bb0115","unstructured":"Lipitor (atorvastatin calcium) tablets for oral administration [package insert] 2009; USA: Dublin, Ireland: Pfizer Ireland Pharmaceuticals. Distributed by Parke-Davis Division of Pfizer Inc., New York, NY; 2009."},{"key":"10.1016\/j.ijcard.2010.08.043_bb0120","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.amjcard.2008.10.029","article-title":"Comparison of efficacy and safety of atorvastatin (80mg) to simvastatin (20 to 40mg) in patients aged<65 versus >=65 years with coronary heart disease (from the Incremental DEcrease through Aggressive Lipid Lowering [IDEAL] study)","volume":"103","author":"Tikkanen","year":"2009","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ijcard.2010.08.043_bb0125","doi-asserted-by":"crossref","first-page":"467","DOI":"10.2165\/00003088-200544050-00002","article-title":"Ezetimibe: a review of its metabolism, pharmacokinetics and drug interactions","volume":"44","author":"Kosoglou","year":"2005","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.ijcard.2010.08.043_bb0130","doi-asserted-by":"crossref","first-page":"E11","DOI":"10.1016\/S1520-765X(01)90107-5","article-title":"Results of phase I\/II clinical trials with ezetimibe, a novel selective cholesterol absorption inhibitor","volume":"3","author":"Stein","year":"2001","journal-title":"Eur Heart J Suppl"},{"key":"10.1016\/j.ijcard.2010.08.043_bb0135","doi-asserted-by":"crossref","first-page":"691","DOI":"10.2217\/1745509X.3.6.691","article-title":"Efficacy and safety of ezetimibe and ezetimibe plus statin therapy in patients aged under 65, 65\u201374 and 75years and older","volume":"3","author":"Robinson","year":"2007","journal-title":"Aging Health"},{"key":"10.1016\/j.ijcard.2010.08.043_bb0140","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1161\/01.CIR.85.4.1293","article-title":"Expanded Clinical Evaluation of Lovastatin (EXCEL) study results. Effect of patient characteristics on lovastatin-induced changes in plasma concentrations of lipids and lipoproteins","volume":"85","author":"Shear","year":"1992","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2010.08.043_bb0145","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/j.amjcard.2005.09.134","article-title":"Phenotypic predictors of response to simvastatin therapy among African\u2013Americans and Caucasians: the Cholesterol and Pharmacogenetics (CAP) study","volume":"97","author":"Simon","year":"2006","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ijcard.2010.08.043_bb0150","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/S0002-9149(02)02599-7","article-title":"Factors affecting low-density lipoprotein and high-density lipoprotein cholesterol response to pravastatin in the West Of Scotland Coronary Prevention Study (WOSCOPS)","volume":"90","author":"Streja","year":"2002","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ijcard.2010.08.043_bb0155","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1001\/archinte.159.16.1893","article-title":"Colesevelam hydrochloride (Cholestagel) \u2014 a new, potent bile acid sequestrant associated with a low incidence of gastrointestinal side effects","volume":"159","author":"Davidson","year":"1999","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.ijcard.2010.08.043_bb0160","first-page":"1","article-title":"Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial","author":"Keech","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.ijcard.2010.08.043_bb0165","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1093\/eurheartj\/ehi397","article-title":"Female-specific aspects in the pharmacotherapy of chronic cardiovascular diseases","volume":"26","author":"Jochmann","year":"2005","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ijcard.2010.08.043_bb0170","doi-asserted-by":"crossref","first-page":"222","DOI":"10.2165\/00003495-199550020-00003","article-title":"Gender effects in pharmacokinetics and pharmacodynamics","volume":"50","author":"Harris","year":"1995","journal-title":"Drugs"},{"key":"10.1016\/j.ijcard.2010.08.043_bb0175","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1161\/CIRCULATIONAHA.107.708388","article-title":"Variation in the 3-hydroxyl-3-methylglutaryl coenzyme a reductase gene is associated with racial differences in low-density lipoprotein cholesterol response to simvastatin treatment","volume":"117","author":"Krauss","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2010.08.043_bb0180","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1177\/000331979704800401","article-title":"Racial differences in risk factors for atherosclerosis \u2014 the ARIC study","volume":"48","author":"Hutchinson","year":"1997","journal-title":"Angiology"},{"key":"10.1016\/j.ijcard.2010.08.043_bb0185","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.amjcard.2005.08.026","article-title":"Comparison of efficacy and safety of rosuvastatin versus atorvastatin in African\u2013American patients in a six-week trial","volume":"97","author":"Ferdinand","year":"2006","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ijcard.2010.08.043_bb0190","first-page":"772","article-title":"Efficacy and safety of coadministration of ezetimibe and simvastatin in African\u2013American patients with primary hypercholesterolemia","volume":"98","author":"Rodney","year":"2006","journal-title":"J Natl Med Assoc"},{"key":"10.1016\/j.ijcard.2010.08.043_bb0195","doi-asserted-by":"crossref","first-page":"2409","DOI":"10.1161\/01.CIR.0000068312.21969.C8","article-title":"Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial","volume":"107","author":"Ballantyne","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2010.08.043_bb0200","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1016\/j.amjcard.2004.02.060","article-title":"Efficacy and safety of ezetimibe co-administered with simvastatin compared with atorvastatin in adults with hypercholesterolemia","volume":"93","author":"Ballantyne","year":"2004","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ijcard.2010.08.043_bb0205","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1185\/030079906X89856","article-title":"Reaching goal in hypercholesterolaemia: dual inhibition of cholesterol synthesis and absorption with simvastatin plus ezetimibe","volume":"22","author":"Daskalopoulou","year":"2006","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.ijcard.2010.08.043_bb0210","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1185\/030079907X210507","article-title":"Meta-analysis of the cholesterol-lowering effect of ezetimibe added to ongoing statin therapy","volume":"23","author":"Mikhailidis","year":"2007","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.ijcard.2010.08.043_bb0215","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.ahj.2004.03.052","article-title":"Achieving lipoprotein goals in patients at high risk with severe hypercholesterolemia: efficacy and safety of ezetimibe co-administered with atorvastatin","volume":"148","author":"Stein","year":"2004","journal-title":"Am Heart J"},{"key":"10.1016\/j.ijcard.2010.08.043_bb0220","doi-asserted-by":"crossref","first-page":"S207","DOI":"10.1046\/j.1523-1755.63.s84.4.x","article-title":"Study of Heart and Renal Protection (SHARP)","author":"Baigent","year":"2003","journal-title":"Kidney Int Suppl"},{"key":"10.1016\/j.ijcard.2010.08.043_bb0225","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1016\/j.ahj.2008.07.023","article-title":"Rationale and design of IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): comparison of ezetimbe\/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes","volume":"156","author":"Cannon","year":"2008","journal-title":"Am Heart J"},{"key":"10.1016\/j.ijcard.2010.08.043_bb0230","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.ijcard.2008.11.048","article-title":"Ethical authorship and publishing","volume":"131","author":"Coats","year":"2009","journal-title":"Int J Cardiol"}],"container-title":["International Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167527310006339?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167527310006339?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T20:28:56Z","timestamp":1759091336000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167527310006339"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,12]]},"references-count":46,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2011,12]]}},"alternative-id":["S0167527310006339"],"URL":"https:\/\/doi.org\/10.1016\/j.ijcard.2010.08.043","relation":{},"ISSN":["0167-5273"],"issn-type":[{"value":"0167-5273","type":"print"}],"subject":[],"published":{"date-parts":[[2011,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Influence of age, gender, and race on the efficacy of adding ezetimibe to atorvastatin vs. atorvastatin up-titration in patients at moderately high or high risk for coronary heart disease","name":"articletitle","label":"Article Title"},{"value":"International Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijcard.2010.08.043","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2010 Elsevier Ireland Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}